Yarger Wealth Strategies LLC Has $299,000 Holdings in Abbott Laboratories (NYSE:ABT)

Yarger Wealth Strategies LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,646 shares of the healthcare product maker’s stock after selling 96 shares during the period. Yarger Wealth Strategies LLC’s holdings in Abbott Laboratories were worth $299,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABT. Edgestream Partners L.P. boosted its holdings in Abbott Laboratories by 506.9% in the 2nd quarter. Edgestream Partners L.P. now owns 15,987 shares of the healthcare product maker’s stock valued at $1,661,000 after purchasing an additional 13,353 shares during the period. Waterloo Capital L.P. grew its position in Abbott Laboratories by 4.6% during the second quarter. Waterloo Capital L.P. now owns 6,670 shares of the healthcare product maker’s stock worth $693,000 after buying an additional 294 shares in the last quarter. Carolinas Wealth Consulting LLC increased its stake in Abbott Laboratories by 12.8% during the second quarter. Carolinas Wealth Consulting LLC now owns 20,580 shares of the healthcare product maker’s stock valued at $2,138,000 after acquiring an additional 2,330 shares during the period. Sienna Gestion lifted its position in shares of Abbott Laboratories by 12.6% in the 2nd quarter. Sienna Gestion now owns 3,801 shares of the healthcare product maker’s stock worth $395,000 after acquiring an additional 424 shares during the period. Finally, Miramar Capital LLC grew its holdings in shares of Abbott Laboratories by 1.5% during the 2nd quarter. Miramar Capital LLC now owns 112,211 shares of the healthcare product maker’s stock worth $11,660,000 after purchasing an additional 1,695 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 2.5 %

Shares of NYSE:ABT opened at $113.85 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The firm has a market cap of $197.47 billion, a P/E ratio of 34.60, a P/E/G ratio of 2.40 and a beta of 0.73. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64. The company’s 50-day moving average price is $115.02 and its two-hundred day moving average price is $112.65.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business had revenue of $10.64 billion during the quarter, compared to analyst estimates of $10.55 billion. During the same quarter last year, the business posted $1.14 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.9% compared to the same quarter last year. As a group, research analysts forecast that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a $0.59 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 2.07%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 66.87%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Raymond James reaffirmed a “buy” rating and issued a $129.00 target price (up from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Piper Sandler raised their price objective on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. Sanford C. Bernstein increased their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Mizuho lifted their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Finally, Evercore ISI raised their target price on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.57.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.